JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v4i1.2314 jpsim.v4i1.2314 Case Report A Study on a 21years Female Patient with Resected Pituitary Macroadenoma Presented with Persistently Raised Growth Hormone Levels and Resistant Diabetes Mellitus Banaras Faizan faizanbanaras958@gmail.com * Fayyaz Ramish Ashfaq Mahnoor Fayaz Khola Tahir Tehrim Raza Ali Allied Ayub Teaching Hospital, Abbottabad, KPK *Correspondence: Faizan Banaras (faizanbanaras958@gmail.com) 13 02 2023 2023 4 1 63 66 15 11 2022 23 11 2022 Copyright © 2023 The Author(s) 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pituitary neuroendocrine tumors affect round about 5% of the general population. Pituitary macroadenomas have a size greater than 10mm, while microadenoma has a size less than 10mm.4 Acromegaly is a rare but fatal disorder mainly due to excessive growth hormone (GH) production from pituitary adenoma and a secondary rise in IGF-1 levels. It is characterized by physical disfigurement mainly face and limbs. The prevalence of acromegaly is 40 to 70 cases per million inhabitants with an annual incidence rate of 3 to 4 per million.5 The treatment options consist of pituitary surgery with the best approach of endonasal transsphenoidal hypophysectomy. The drugs used for prolactinoma and somatotrophic adenoma are dopamine agonists and somatostatin analogues respectively.

 References Asa SL (2011) Tumors of the Pituitary Gland. AFIP Atlas of Tumor Pathology. IV Series Armed Forces Institute of Pathology. Washington DC. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011 Neuro-oncol. 2014;16(4):63. Chiloiro S, Doglietto F, Trapasso B, Lacovazzo D, Giampietro A, Di Nardo F, et al Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinol. 2015;101(2):143- 50. Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al.; attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an international pituitary pathology club proposal. Endocr Relat Cancer. 2016;24: C5–C8. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999; 2(1):29-41 Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws Jr ER, Groover RV et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab. 1994;79(4):1135-40. Hardy J. Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO, Ross GT (eds) Diagnosis and Treatment of Pituitary Tumors. International Congress Series No. 303. Exerpta Medica, Amsterdam, 1973; pp 179–198. Chnasen P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3(1):1-17. Scacchi M, Cavagnini F. Aromrgaly. Pituitary. 2006;9(3):297-303. Scully C, Cawson RA. Medical problems in dentistry. 5th edition Elsevier, St Louis. 2005; pp. 95-6. Ross DA & Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. Journal of Neurosurgery 1988;68(5):854-67. Valdemarsson S, Bramnert M, Cronquist S, Elner A, Eneroth CM, Hedner P, Lindvall-Axelsson M, Nordstrom CH & Stromblad LG. Early postoperative basal serum GH level and the GH response to TRH in relation to the long-term outcome of surgical treatment for acromegaly: a report on 39 patients. J Intern Med. 1991;230(1):49-54. Fahlbusch R, Honegger J & Buchfelder M. Surgical management of acromegaly. Endocrinol Metabol Clin North Am. 1992;21(5):669-92. Arafah BM, Rosenzweig JL, Fenstermaker R, Salazar R, McBride CE & Selman W. Value of growth hormone dynamics and somatostatin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly. J Lab Clin Med. 1987;109(3):346-54.